Cargando…
Analgesic efficacy of imrecoxib for postoperative pain following oral surgery: a prospective randomized, active-controlled, non-inferiority trial
BACKGROUND: Imrecoxib, a novel cyclooxygenase (COX-2) selective non-steroidal anti-inflammatory drug (NSAID), has been approved in China for more than 9 years. This study aimed to assess the efficacy and safety of imrecoxib compared with celecoxib for patients with moderate or severe acute pain foll...
Autores principales: | Jiang, Yu, Qi, Lili, Liu, Jie, Wu, Heming, Li, Yi, Zou, Linhu, Guo, Zhiwei, Wang, Jinqiang, Li, Huaiqi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8039693/ https://www.ncbi.nlm.nih.gov/pubmed/33850866 http://dx.doi.org/10.21037/atm-21-264 |
Ejemplares similares
-
Imrecoxib attenuates bleomycin-induced pulmonary fibrosis in mice
por: Miao, Yang, et al.
Publicado: (2023) -
Cost-utility analysis of imrecoxib compared with diclofenac for patients with osteoarthritis
por: Sun, Xueshan, et al.
Publicado: (2021) -
A Real-World Study on the Effect of Imrecoxib for Patients with Axial Spondyloarthritis
por: Zong, He-xiang, et al.
Publicado: (2022) -
The Efficacy of Imrecoxib and Celecoxib in Axial Spondyloarthritis and Their Influence on Serum Dickopff-Related Protein 1 (DKK-1) Levels
por: Gao, Guan-Min, et al.
Publicado: (2017) -
Comparative Pharmacokinetics and Safety of Imrecoxib, a Novel Selective Cyclooxygenase-2 Inhibitor, in Elderly Healthy Subjects
por: Yang, Ling, et al.
Publicado: (2022)